SURUNKALI BUYRAK KASALLIGI BILAN OG‘RIGAN BOLALARDA OQSIL-ENERGETIK YETISHMOVCHILIKNI ERTA BASHORAT QILISH: FAZA BURCHAGI VA PREALBUMIN ASOSIDA ROC-TAHLLI

Kamola Po‘latova

Authors

Kamola Po‘latova ilmiy xodim, №1 Toshkent davlat tibbiyot universiteti, Oilaviy shifokorlik, jismoniy tarbiya va fuqarolar muhofazasi kafedrasi Author

Keywords:

surunkali buyrak kasalligi, oqsil-energetik yetishmovchilik, faza burchagi, prealbumin

Abstract

Maqsad: Surunkali buyrak kasalligi (SBK) bilan og‘rigan bolalarda oqsil-energetik yetishmovchilikni (OEY) erta bashorat qilishda faza burchagi va prealbuminning prognostik ahamiyatini baholash hamda optimal chegara qiymatlarini aniqlash.
Material va usullar: Tadqiqotga 7 yoshdan 17 yoshgacha bo‘lgan SBK bilan og‘rigan 124 nafar bola va 20 nafar sog‘lom nazorat guruhi kiritildi. Barcha bemorlarda antropometrik o‘lchovlar (Z-score HAZ, WAZ, BAZ), bioimpedansometriya (faza burchagi, ECW/TBW) va laborator tekshiruvlar (prealbumin, albumi
n, transferrin) o‘tkazildi. Prognostik ahamiyat ROC-tahlil yordamida baholandi. Statistik ishlov Statistica 13.0 va SPSS 26.0 dasturlarida amalga oshirildi.
Natijalar: SBK bilan og‘rigan bolalarda OEY 19,4% holatda qayd etildi. Faza burchagi (AUC=0,864; 95% II: 0,782–0,946) va prealbumin (AUC=0,842; 95% II: 0,756–0,928) eng yuqori prognostik ahamiyatga ega bo‘ldi. Optimal chegara qiymatlari: faza burchagi uchun <4,6 , prealbumin uchun <192 mg/l. Ikkala ko‘rsatkichning kombinatsiyasi prognostik aniqlikni AUC=0,912 gacha oshirdi (p=0,024). Faza burchagi <4,6 va prealbumin <192 mg/l kombinatsiyasida OEY ehtimoli 86,4% ga yetdi.
Xulosa: Faza burchagi va prealbumin SBK bilan og‘rigan bolalarda OEY ni erta bashorat qilishning yuqori sezgir va o‘ziga xos markerlari hisoblanadi. Ularning kombinatsiyalangan qo‘llanilishi prognostik aniqlikni sezilarli darajada oshiradi va klinik amaliyotda xavf guruhlarini stratifikatsiya qilish imkonini beradi.

Downloads

Download data is not yet available.

References

1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2019 // The Lancet. – 2020. – Vol.395. – P.709-733.

2. Saran R., Robinson B., Abbott K.C. et al. US Renal Data System 2020 Annual Data Report // American Journal of Kidney Diseases. – 2020. – Vol.75(1 Suppl 1). – S1-S64.

3. Greenbaum L.A., Benador N., Warady B.A. Nutritional management of pediatric CKD // Pediatric Nephrology. – 2021. – Vol.36. – P.1231-1245.

4. Rees L., Shaw V. Nutrition in children with CKD: recent advances // Current Opinion in Clinical Nutrition & Metabolic Care. – 2019. – Vol.22. – P.205-211.

5. Kovesdy C.P., Kopple J.D., Kalantar-Zadeh K. Management of protein-energy wasting in CKD // Nature Reviews Nephrology. – 2017. – Vol.13. – P.90-102.

6. Stenvinkel P., Ikizler T.A. Inflammation in end-stage renal disease // Kidney International. – 2019. – Vol.95. – P.502-510.

7. Foster B.J., Leonard M.B., Zemel B.S. Anthropometric assessment in pediatric CKD // Clinical Journal of the American Society of Nephrology. – 2020. – Vol.15. – P.295-303.

8. KDIGO 2020 Clinical Practice Guideline for CKD Evaluation and Management // Kidney International Supplements. – 2020. – Vol.10(4). – P.1-115.

9. Nelms C.L., Sucher K.P., Lacey K. Nutrition therapy in CKD // Journal of Renal Nutrition. – 2021. – Vol.31. – P.1-10.

10. Kyle U.G., Bosaeus I., De Lorenzo A.D. et al. Bioelectrical impedance analysis – part II: utilization in clinical practice // Clinical Nutrition. – 2004. – Vol.23(6). – P.1430-1453.

11. Ingenbleek Y., Young V. Transthyretin (prealbumin) in health and disease: nutritional implications // Annual Review of Nutrition. – 1994. – Vol.14. – P.495-533.